Whalesbook
Laurus Labs has released the audio recording of its Q4 FY26 earnings call, offering investors direct access to management's commentary following strong financial results.
For the period, the company reported consolidated revenue of ₹1,812 crore and a net profit of ₹279 crore for Q4 FY26, marking a 19% increase year-on-year. For the full fiscal year FY26, Laurus Labs achieved a consolidated net profit of ₹889 crore, up 148% from FY25, on revenues that grew 23% to ₹6,813 crore. Growth was notably driven by its Contract Development and Manufacturing Organization (CDMO) and Affordable Medicines (Generics) divisions. The board also approved a second interim dividend of ₹1.20 per share for FY26.
The availability of the call recording offers investors direct access to management's detailed commentary on these results. This provides deeper insights into the company's performance drivers, strategic initiatives, R&D efforts, and market dynamics beyond the official financial figures.
Brokerage firm Motilal Oswal initiated coverage with a 'Buy' rating and a target price of ₹1,280, acknowledging anticipated growth. However, the stock's current valuation is considered high relative to peers, presenting a point for investors to monitor.
Key areas for investors to track include management's outlook on the CDMO business pipeline and commercial supplies, progress in new technology investments such as peptides and gene therapy, and the performance of Generics and API segments. Sustaining growth will depend on continued execution on CDMO contracts and expansion into new therapeutic areas, alongside managing potential market volatility.
Laurus Labs operates in a competitive pharmaceutical landscape, differentiating itself through integrated offerings in APIs, generics, and CDMO services, with a growing focus on high-value segments.